Compare Incyte Corporation (INCY) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Clear Secure Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Clear Secure Inc trades at $46.22 (market cap $4.98B). The key difference: Incyte Corporation is far larger — about 4.9× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | YOU | |
|---|---|---|
Market Cap | $24.54B | $4.98B |
Sector | Health | Technology |
52-Week High | $129.93 | $62.36 |
52-Week Low | $81.61 | $29.61 |
Enterprise Value | $20.04B | $4.13B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
CLEAR Secure (YOU) trades at $46.16, down 9.86% in the past 24 hours, approaching key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating expectations at $0.49 per share versus $0.40 expected, driven by 66.66% gross margins and 90.29% ROE. Recent news highlights enterprise expansion including corporate membership launches and airport service investments.
Outlook remains positive with revenue growth accelerating to $1.0B in 2026 and analyst consensus leaning bullish (44% Buy ratings). Key risks include competitive pressure in identity verification and execution of new corporate initiatives. The current dip may present a buying opportunity for growth investors given strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
